Lorena Olivares

Dr. Lorena Olivares

Principe Felipe Research Centre (CIPF)
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LOLorena Olivares
Lorena Olivares
SGSheyla Gomariz
Sheyla Gomariz
ICIsabel Campillo
Isabel Campillo
Regina RodrigoRegina Rodrigo
Regina Rodrigo
Inherited retinal dystrophies (IRDs) are a group of retinal disorders that cause progressive and severe loss of vision because of retinal cell death, mainly photoreceptor cells. IRDs include retinitis pigmentosa (RP), the most common IRD. IRDs present a genetic and clinical heterogeneity that makes it difficult to achieve proper treatment. The progression of IRDs is influenced, among other factors, by the activation of the immune cells (microglia, macrophages, etc.) and the release of inflammatory molecules such as chemokines and cytokines. Upregulation of tumor necrosis factor alpha (TNFα), a pro-inflammatory cytokine, is found in IRDs. This cytokine may influence photoreceptor cell death. Different cell death mechanisms are proposed, including apoptosis, necroptosis, pyroptosis, autophagy, excessive activation of calpains, or parthanatos for photoreceptor cell death. Some of these cell death mechanisms are linked to TNFα upregulation and inflammation. Therapeutic approaches that reduce retinal inflammation have emerged as useful therapies for slowing down the progression of IRDs. We focused this review on the relationship between retinal inflammation and the different cell death mechanisms involved in RP. We also reviewed the main anti-inflammatory therapies for the treatment of IRDs.

14 July 2015 in Scientific Reports
Verified
Journal Article
Open access
CCCristina Martínez-Fernández de la Cámara
Cristina Martínez-Fernández de la Cámara
AHAlberto Miguel Hernández-Pinto
Alberto Miguel Hernández-Pinto
LOLorena Olivares
Lorena Olivares
CCCarmen Cuevas-Martín
Carmen Cuevas-Martín
MSMaría Sánchez-Aragó
María Sánchez-Aragó
Regina RodrigoRegina Rodrigo
Regina Rodrigo
Growing evidence suggests that inflammation is involved in the progression of retinitis pigmentosa (RP) both in patients and in animal models. The aim of this study was to investigate the effect of Adalimumab, a monoclonal anti-TNFα antibody, on retinal degeneration in a murine model of human autosomal recessive RP, the rd10 mice at postnatal day (P) 18. In our housing conditions, rd10 retinas were seriously damaged at P18. Adalimumab reduced photoreceptor cell death, as determined by scoring the number of TUNEL-positive cells. In addition, nuclear poly (ADP) ribose (PAR) content, an indirect measure of PAR polymerase (PARP) activity, was also reduced after treatment. The blockade of TNFα ameliorated reactive gliosis, as visualized by decreased GFAP and IBA1 immunolabelling (Müller cell and microglial markers, respectively) and decreased up-regulation of TNFα gene expression. Adalimumab also improved antioxidant response by restoring total antioxidant capacity and superoxide dismutase activity. Finally, we observed that Adalimumab normalized energetic and metabolic pattern in rd10 mouse retinas. Our study suggests that the TNFα blockade could be a successful therapeutic approach to increase photoreceptor survival during the progression of RP. Further studies are needed to characterize its effect along the progression of the disease.

20 August 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
LOLorena Olivares
Lorena Olivares
SVSheyla Velasco
Sheyla Velasco
JMJosé María Millán
José María Millán
Regina RodrigoRegina Rodrigo
Regina Rodrigo
Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies characterized by the progressive and irreversible loss of vision. We previously found that intraperitoneal administration of Adalimumab, a monoclonal anti‐TNFα antibody, slowed down retinal degeneration in the murine model of RP, the rd10 mice. The aims of this study were to improve its neuroprotective effect and to deepen understanding of the molecular mechanisms involved in this effect. We analyzed (i) the in vitro effect of Adalimumab on the TNFα‐mediated cell death in retinal cells; (ii) the effect of a single intravitreal injection of Adalimumab on retinal degeneration in rd10 mice at postnatal day (P) 23. In vitro studies showed that TNFα induced caspase and poly ADP ribose polymerase (PARP) activation, downregulation of (kinase receptor‐interacting protein 1) RIPK1 and upregulation of RIPK3 in retinal cells. Adalimumab reduced cell death probably through the inhibition of caspase 3 activation. In vivo studies suggested that PARP and NLRP3 inflammasome are mainly activated and to a lesser extent caspase‐dependent mechanisms in rd10 retinas at P23. Necroptosis seems to be inhibited by the downregulation of RIPK1. Adalimumab prevented from retinal degeneration without affecting caspase ‐dependent mechanisms but decreasing PARP activation, microglia activation as well as NLRP3 inflammasome.

8 January 2018 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
LOLorena Olivares
Lorena Olivares
CCCristina Martínez‐Fernandez de la Ca´mAra
Cristina Martínez‐Fernandez de la Ca´mAra
DHDavid Hervás
David Hervás
JMJose´ Mar´a Milla´n
Jose´ Mar´a Milla´n
Regina RodrigoRegina Rodrigo
Regina Rodrigo
Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies characterized by progressive and irreversible loss of vision due to rod and cone degeneration. Evidence suggests that an inappropriate oxygen level could contribute to its pathogenesis. Rod cell death could increase oxygen concentration, reduce hypoxia‐inducible factor 1 (HIF‐1α) and contribute to cone cell death. The purposes of this study were: 1 ) to analyze the temporal profile of HIF‐1α, its downstream effectors VEGF, endothelin‐1 (ET‐1), iNOS, and glucose transporter 1 (GLUT1), and neuroinflammation in retinas of the murine model of rd10 (retinal degeneration 10 ) mice with RP; 2) to study oxygen bioavailability in these retinas; and 3) to investigate how stabilizing HIF‐1α proteins with dimethyloxaloglycine (DMOG), a prolyl hydroxylase inhibitor, affects retinal degeneration, neuroinflammation, and antioxidant response in rd10 mice. A generalized down‐regulation of HIF‐1α and its downstream targets was detected in parallel with reactive gliosis, suggesting high oxygen levels during retinal degeneration. At postnatal d 18, DMOG treatment reduced photoreceptor cell death and glial activation. In summary, retinas of rd10 mice seem to be exposed to a hyperoxic environment even at early stages of degeneration. HIF‐1α stabilization could have a temporal neuroprotective effect on photoreceptor cell survival, glial activation, and antioxidant response at early stages of RP.—Olivares‐Gonza´lez, L., Mart´nez‐Fernandezdela Ca´mara, C., Herva´s, D., Milla´n, J. M., Rodrigo, R. HIF‐1α stabilization reduces retinal degeneration in a mouse model of retinitis pigmentosa. FASEB J. 32, 2438–2451 (2018). www.fasebj.org

26 June 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
LOLorena Olivares
Lorena Olivares
SGSheyla Gomariz
Sheyla Gomariz
ICIsabel Campillo
Isabel Campillo
DSDavid Salom
David Salom
EGEmilio González-García
Emilio González-García
Regina RodrigoRegina Rodrigo
Regina Rodrigo
Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies characterized by progressive degeneration of photoreceptor cells. Ocular redox status is altered in RP suggesting oxidative stress could contribute to their progression. In this study, we investigated the effect of a mixture of nutraceuticals with antioxidant properties (NUT) on retinal degeneration in rd10 mice, a model of RP. NUT was orally administered to rd10 mice from postnatal day (PD) 9 to PD18. At PD18 retinal function and morphology were examined by electroretinography (ERG) and histology including TUNEL assay, immunolabeling of microglia, Müller cells, and poly ADP ribose polymers. Retinal redox status was determined by measuring the activity of antioxidant enzymes and some oxidative stress markers. Gene expression of the cytokines IL-6, TNFα, and IL-1β was assessed by real-time PCR. NUT treatment delayed the loss of photoreceptors in rd10 mice partially preserving their electrical responses to light stimuli. Moreover, it ameliorated redox status and reduced inflammation including microglia activation, upregulation of cytokines, reactive gliosis, and PARP overactivation. NUT ameliorated retinal functionality and morphology at early stages of RP in rd10 mice. This formulation could be useful as a neuroprotective approach for patients with RP in the future.

10 October 2014 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
CCCristina Martínez-Fernández de la Cámara
Cristina Martínez-Fernández de la Cámara
LOLorena Olivares
Lorena Olivares
DHDavid Hervás
David Hervás
DSDavid Salom
David Salom
JMJose Millan
Jose Millan
Regina RodrigoRegina Rodrigo
Regina Rodrigo
CGMP-degrading phosphodiesterase 6 (PDE6) mutations cause around 4 to 5% of retinitis pigmentosa (RP), a rare form of retinal dystrophy. Growing evidence suggests that inflammation is involved in the progression of RP. The aims of this study were to corroborate the presence of high TNFΑ concentration in the eyes of RP patients and to evaluate whether the blockade of TNFΑ with Infliximab, a monoclonal anti-TNFΑ antibody, prevented retinal degeneration induced by PDE6 inhibition in cultures of porcine retina. Aqueous humor from 30 patients with RP and 13 healthy controls were used to quantify the inflammatory mediators IL-6, TNFΑ, IL-1Β, IL-10 by a multiplex enzyme-linked immunosorbent assay (ELISA) system. Retinal explants from pig were exposed to Zaprinast, a PDE6 inhibitor, for 24 hours in the absence or the presence of Infliximab. Cell death was evaluated by TUNEL assay. The number and distribution of caspase-3 positive cells, indirect poly(ADP)ribose polymerase (PARP) activation and glial fibrillary acidic protein (GFAP) content were visualized by immunolabeling. Antioxidant total capacity, nitrites and thiobarbituric acid reactive substances (TBARS) formation were determined to evaluate antioxidant-oxidant status. IL-6 and TNFΑ concentrations were higher in the aqueous humor of RP patients than in controls. Infliximab prevented retinal degeneration, as judging by the reduced presence of TUNEL-positive cells, the reduction of caspase-3 activation and also reduction of glial activation, in an ex vivo model of porcine retina. Additionally, Infliximab partially reduced oxidative stress in retinal explants exposed to Zaprinast. Inflammatory mediators IL-6 and TNFΑ were elevated in the aqueous humor of RP patients corroborating previous studies suggesting sustained chronic inflammation. Our study suggests that TNFΑ is playing an important role in cell death in an ex vivo model of retinal degeneration by activating different cell pathways at different cell layers of the retina that should be further studied.